Aaron Michael Ring
41Patents
9h-index
30Co-inventors
71Inventor score
Filing activity: Dec 22, 2011 → Mar 8, 2023
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US9428567B2 | Antagonists of interleukin-2 receptor | Human Necessities | 39 | Active |
| US10081680B2 | Anti-SIRP-alpha antibodies and bispecific macrophage enhancing antibodies | Physics | 37 | Active |
| US9845345B2 | SIRP polypeptide compositions and methods of use | Chemistry; Metallurgy | 36 | Active |
| US9562087B2 | High affinity PD-1 agents and methods of use | Chemistry; Metallurgy | 34 | Active |
| US9546206B2 | High affinity PD-1 agents and methods of use | Chemistry; Metallurgy | 26 | Active |
| US10150802B2 | Superagonists, partial agonists and antagonists of interleukin-2 | Chemistry; Metallurgy | 16 | Active |
| US10183980B2 | Superagonists and antagonists of interleukin-2 | Human Necessities | 15 | Active |
| US10781256B2 | Anti SIRP-α antibodies and bi-specific macrophage enhancing antibodies | Physics | 14 | Active |
| US9944911B2 | High affinity Sirp-alpha reagents and methods of using | Physics | 10 | Active |
| US10774125B2 | SIRP-gamma polypeptide compositions and methods of use | Chemistry; Metallurgy | 9 | Active |
| US10316094B2 | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance | Emerging Cross-Sectional Technologies | 8 | Active |
| US10611842B2 | Disrupting FC receptor engagement on macrophages enhances efficacy of anti-SIRPα antibody therapy | Chemistry; Metallurgy | 7 | Active |
| US10406179B2 | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling | Chemistry; Metallurgy | 7 | Active |
| US10618976B2 | SIRP-α agonist antibody | Chemistry; Metallurgy | 5 | Active |
| US10800830B2 | High affinity PD-1 agents and methods of use | Chemistry; Metallurgy | 5 | Active |
| US11208481B2 | High affinity SIRP-alpha reagents and methods of using | Physics | 4 | Active |
| US10654905B2 | Method of treating graft versus host disease with an interleukin-2 mutein | Chemistry; Metallurgy | 2 | Active |
| US11850276B2 | Interleukin-18 variants and methods of use | Emerging Cross-Sectional Technologies | 2 | Active |
| US11419897B2 | Engraftment of stem cells with a combination of an agent that targets stem cells and modulation of immunoregulatory signaling | Chemistry; Metallurgy | 1 | Active |
| US10889649B2 | Compositions and methods for inducing phagocytosis of MHC class I positive cells and countering anti-CD47/SIRPA resistance | Chemistry; Metallurgy | 1 | Active |
| US11117943B2 | Superagonists and antagonists of interleukin-2 | Human Necessities | 1 | Active |
| US11407801B2 | SIRP-gamma polypeptide compositions and treatment of cancer | Chemistry; Metallurgy | 1 | Active |
| US11384131B2 | Superagonists, partial agonists and antagonists of interleukin-2 | Chemistry; Metallurgy | 1 | Active |
| US10520516B2 | Complexes comprising transmembrane receptors and antibodies that bind the receptors in a conformationally selective manner | Physics | 0 | Active |
| US12029778B2 | Interleukin-18 mimics and methods of use | Physics | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.